01Identity
Which preparation?
Brand, active and inactive ingredients, concentration, batch and product information identify the material.
Hair Mesotherapy · Istanbul
Hair Mesotherapy · Istanbul
Hair Mesotherapy
Hair mesotherapy describes a scalp injection route, not one medicine. The exact product, ingredients, concentration, intended route, legal status and measurable purpose must be known before the method can be assessed.
Vitamins, peptides, minoxidil and 5-alpha-reductase inhibitors are not interchangeable. Evidence and risk remain attached to the individual preparation and route.
Quick Orientation
Four facts before injection
Without product, route, diagnosis and endpoint, mesotherapy is incomplete.
A result for one ingredient and protocol cannot be extended to an unnamed cocktail or another pattern of hair loss.
02Diagnosis
Which hair diagnosis?
Pattern, diffuse, inflammatory and scarring hair loss do not share one injectable mixture.
03Status
Which authorised route?
Approval for a tablet or topical form does not automatically include intradermal scalp injection.
04Review
Which endpoint?
Hair findings and comparable images are defined before treatment, not selected afterwards.
What Hair Mesotherapy Means
Local delivery · heterogeneous products
Hair mesotherapy is an administration method, not one standard therapy.
The term covers superficial intradermal or subcutaneous injections of different medicines, nutrients, peptides or mixed preparations. Composition and technique can differ substantially.
What may be assessed
- Match one fully identified preparation to a limited scalp target
- Be considered as an adjunct after a specific hair diagnosis
- Keep concentration, amount, depth, area and batch traceable
- Use separate safety and hair-outcome review points
What the route cannot prove
- Replace diagnosis of unexplained or scarring hair loss
- Turn different ingredients into an equivalent cocktail
- Remove contraindications, interactions or off-label considerations
- Guarantee new follicles, density or lasting change
Local injection is not proof of local-only action, effectiveness or safety. Every substance retains its own contraindications, interactions and evidence limits.
Medical Suitability
Diagnosis · scalp · product · priority
Five checks come before any scalp microinjection.
A personal examination and original product review determine whether injection is defensible and whether another pathway should take priority.
- 01
Review course and triggers
Onset, pace, family history, health, medicines, nutrition, life stage and previous treatment are considered.
- 02
Examine hair and scalp
Miniaturisation, inflammation, infection, scaling, scarring and breakage are assessed.
- 03
Verify the product
Name, ingredients, strength, manufacturer, batch, expiry, storage and original documents are checked.
- 04
Clarify route and status
Intended formulation, indication and injection route are separated, including any off-label use.
- 05
Set priority and endpoint
Established options, the target area, image standard and stopping criteria are agreed first.
Product and Administration
Original container · exact amount · scalp route
Traceability runs from the labelled product to the treatment zone.
Decanting or mixing does not make a product clearer. Identity, compatibility, sterility, route and administered amount are recorded before use.
01Product
Check the sealed preparation
The process begins with the original label, manufacturer information and intended formulation.
- Record name, batch and expiry
- Check active and inactive ingredients
- Explain route and current status
02Plan
Give one product one task
Concentration, total amount, target area, depth and spacing are justified for the identified preparation.
- Avoid anonymous cocktails
- Do not assume mixing compatibility
- Assess combinations separately
03Injection
Use an aseptic, measurable route
Scalp preparation, single-use equipment, distribution and immediate response are documented.
- Use appropriate skin antisepsis
- Record zone and delivery depth
- Provide aftercare boundaries
A long ingredient list is not a quality measure. Clinical review requires an identifiable product, a justified route and a reproducible record.
Evidence and Limits
Ingredient-specific studies · variable protocols
A signal for one injected medicine does not validate hair mesotherapy as a whole.
Clinical studies investigate different active ingredients, concentrations, depths, schedules and comparators. Results and adverse effects therefore remain product-specific.
Keep diagnoses separate
Most injectable studies concern androgenetic alopecia and cannot be extended to other causes.
Keep ingredients separate
Findings for dutasteride, minoxidil, peptides or nutrient mixtures are not interchangeable.
Recognise limited designs
Small groups, varied controls and short follow-up restrict comparison and certainty.
Include reported harm
Dermatitis, local inflammation, paradoxical loss and scarring have been described with some protocols.
Current evidence does not define one routine cocktail or schedule. The exact product must be weighed against established treatment and no injection.
Individual Treatment Plan
Product-specific start and stop rules
An injection series should not begin without a reason to end it.
Frequency is not inherited from a package. Diagnosis, product, tolerability and objective review determine whether any further step is reasonable.
Record the baseline
Document diagnosis, scalp target, imaging, current treatment and the exact product.
Limit the first phase
Give one preparation a defined role, timeframe and review date.
Review safety separately
Scalp reactions and possible systemic effects are not counted as hair benefit.
Make a new decision
Without a relevant and tolerable signal, pause, change direction or stop rather than repeat automatically.
Course and Follow-Up
Scalp response · hair cycle · objective comparison
Injection effects and hair outcomes belong to different timeframes.
The scalp is reviewed early for complications. Hair density or shaft change, if relevant, requires later standardised assessment.
- 01Early
Hours to days
Burning, tenderness, small papules, redness, swelling or bruising may occur.
- 02Safety
Days to weeks
Persistent inflammation, dermatitis, lumps, focal loss or product-related symptoms require assessment.
- 03Hair endpoint
Following months
Lighting, parting, hair length and any imaging method are kept comparable.
- 04Decision
At the review point
Tolerability, objective findings, burden and alternatives determine whether treatment continues.
Risks and Alternatives
Needle risk · product action · personal factors
A scalp injection is not necessarily local in effect.
Consent combines procedure-related risks with the contraindications, interactions and possible systemic effects of the exact substance.
01Procedure
Injection and sterility
Pain, bleeding, swelling, bruising, infection, dermatitis, nodules and scarring are possible.
02Preparation
Product and patient
Allergy, medicines, pregnancy potential and product-specific hormonal or systemic risks require review.
03Order
Clinical alternatives
Cause-directed treatment, licensed medicine, scalp care, observation or surgery may take priority.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
New, increasing or unexpected symptoms after injection need timely in-person medical assessment and product-specific documentation.
Istanbul and Follow-Up
Original product and later review
The injection is one part of a diagnosis-led pathway.
International planning links the examination, product decision, administration record, aftercare and later comparison.
01Before travel
Organise current information
Treatment history, allergies and existing clinical records help frame the in-person questions.
02Bağdat Caddesi
Examine scalp and product
Diagnosis, original documents, route, alternatives and the intended endpoint are reviewed.
03Treatment day
Record any administration
If suitable, batch, amount, area, depth, pattern and immediate response are documented.
04After return
Plan a comparable review
Aftercare boundaries, warning signs, contact route and assessment timing are agreed.
The Doctor Aslan Approach
Product transparency before cocktail language
The diagnosis, preparation and route are assessed—not the label mesotherapy.
A scalp injection is considered only when the hair-loss cause is sufficiently clear, the product is fully identified and its role against established options can be justified.
Diagnosis before injection
Active inflammation, scarring or a treatable cause changes the priority.
Show the whole product
Ingredients, concentration, batch, storage, route and status remain visible.
One product, one purpose
A mixture is not justified by the length of its ingredient list.
Stop before repeating
Continuation requires tolerability and a relevant finding at the agreed review.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about hair mesotherapy; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Hair Mesotherapy?+
Hair Mesotherapy is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Hair Mesotherapy?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Name the diagnosis · name the product · name the route